BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34502191)

  • 1. NLRP3 Deficiency in Hepatocellular Carcinoma Enhances Surveillance of NK-92 through a Modulation of MICA/B.
    Lee HH; Kim D; Jung J; Kang H; Cho H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
    Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
    Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.
    Fang L; Gong J; Wang Y; Liu R; Li Z; Wang Z; Zhang Y; Zhang C; Song C; Yang A; Ting JP; Jin B; Chen L
    J Exp Clin Cancer Res; 2014 Sep; 33(1):76. PubMed ID: 25228093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
    Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
    Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
    Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
    Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anterior gradient 2-derived peptide upregulates major histocompatibility complex class I-related chains A/B in hepatocellular carcinoma cells.
    Bian J; He L; Wu Y; Liu W; Ma H; Sun M; Yu J; Yu Z; Wei M
    Life Sci; 2020 Apr; 246():117396. PubMed ID: 32035130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
    Goto K; Annan DA; Morita T; Li W; Muroyama R; Matsubara Y; Ito S; Nakagawa R; Tanoue Y; Jinushi M; Kato N
    Sci Rep; 2016 Dec; 6():38407. PubMed ID: 27910927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
    Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
    Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.
    Jinushi M; Takehara T; Tatsumi T; Kanto T; Groh V; Spies T; Kimura R; Miyagi T; Mochizuki K; Sasaki Y; Hayashi N
    Int J Cancer; 2003 Apr; 104(3):354-61. PubMed ID: 12569559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
    Shin S; Kim M; Lee SJ; Park KS; Lee CH
    Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
    Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
    Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
    Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
    Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA.
    Wan LL; Zhang DQ; Zhang JN; Ren LQ
    J Zhejiang Univ Sci B; 2017 Jun; 18(6):522-531. PubMed ID: 28585428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-506 Promotes Natural Killer Cell Cytotoxicity against Human Hepatocellular Carcinoma Cells by Targeting STAT3.
    Su Z; Ye X; Shang L
    Yonsei Med J; 2019 Jan; 60(1):22-29. PubMed ID: 30554487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAC1
    Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
    Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
    Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation.
    Li P; Liu Y; He Q
    Drug Des Devel Ther; 2020; 14():1609-1620. PubMed ID: 32425506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.